Medical Device Reimbursement and How to Recruit Payer Experts
Medical device reimbursement is how a device gets paid for after FDA clearance or approval. It needs a billing code (CPT or HCPCS), a coverage decision (NCD, LCD, or commercial policy), and a payment rate. Recruiting payer experts, such as former health plan medical directors, ex-CMS officials, coding specialists, and HEOR leads, shows how those decisions actually get made.
The Three Decisions Behind Medical Device Reimbursement
Medical device reimbursement is the system that decides whether, and how much, a payer pays for a device and the procedure that uses it. The system rests on three separate decisions: a code that identifies the service, a coverage policy that says when the payer will pay, and a payment rate that sets the amount.
FDA clearance or approval does not trigger any of these decisions. In its final notice on the TCET pathway, CMS said it applies different standards than the FDA. It also said FDA approval or clearance alone does not entitle a technology to Medicare coverage.
| Pillar | Question it answers | Who decides (US) | Typical instruments |
|---|---|---|---|
| Coding | How is the service described on a claim? | AMA CPT Editorial Panel; CMS for HCPCS Level II | CPT Category I and III; HCPCS Level II |
| Coverage | Under what conditions will the payer pay? | CMS, Medicare Administrative Contractors (MACs), commercial plans | NCDs, LCDs, commercial medical policies |
| Payment | How much is paid, and to whom? | CMS payment systems; commercial contracts | MS-DRGs, APCs, physician fee schedule, NTAP, pass-through |
Each pillar has its own experts. That is why a single “payer expert” rarely covers a whole device reimbursement question.
How Does Medical Device Reimbursement Work in the US?
US medical device reimbursement works in sequence. A procedure or device gets a code, a payer publishes or applies a coverage rule, and a payment system sets the amount by site of care (inpatient, outpatient, physician office, or home). Medicare usually sets the reference point, and commercial plans write their own medical policies.
Coding: CPT and HCPCS Level II
CPT codes (Current Procedural Terminology, maintained by the American Medical Association) describe procedures and professional services. HCPCS Level II codes (maintained by CMS) describe supplies, equipment, and some device categories.
CPT Category I codes cover established procedures.
CPT Category III codes are temporary tracking codes for emerging technology. In 2026, the AMA increased Category III releases from twice to three times a year. It also cut the gap between release and effective date from six months to three months.
HCPCS Level II applications for non-drug, non-biological items follow CMS’s twice-yearly coding cycles. Drugs and biologicals follow quarterly cycles.
Coverage: NCDs, LCDs, and Commercial Medical Policy
A National Coverage Determination (NCD) is a CMS policy that binds Medicare nationwide. A Local Coverage Determination (LCD) is issued by a regional Medicare Administrative Contractor (MAC) for its own jurisdiction. LCDs apply where no NCD settles the question.
| Feature | NCD | LCD | Commercial medical policy |
|---|---|---|---|
| Issued by | CMS | A MAC | Each health plan |
| Geographic scope | National | One MAC jurisdiction | Plan’s book of business |
| Binds Medicare Advantage? | Yes | Yes, within the plan’s service area | Not applicable |
| Typical trigger | Formal request or CMS initiative | MAC policy development | Plan technology assessment cycle |
Medicare Advantage plans must follow NCDs and LCDs. The CMS Contract Year 2024 final rule added 42 CFR 422.101(b)(6). Under it, plans may use their own internal coverage criteria only when Medicare criteria are “not fully established,” and those criteria must be publicly accessible. This matters for research design: KFF reports that 54% of eligible Medicare beneficiaries (34.1 million people) were in Medicare Advantage in 2025.
Payment: DRGs, APCs, NTAP, and Pass-Through
Medicare pays hospitals largely fixed amounts per case. Inpatient stays are paid by MS-DRG and outpatient services by APC. A costly new device can be underpaid until those rates catch up.
Two temporary mechanisms close that gap:
- the New Technology Add-on Payment (NTAP) for inpatient care;
- transitional pass-through payment for hospital outpatient care.
The FY 2027 IPPS final rule (July 31, 2026) also changed NTAP. CMS repealed the “alternative pathway” that let FDA Breakthrough Devices skip the substantial-clinical-improvement test. The repeal applies from FY 2028 applications, with a limited transition.
Prior Authorization and Utilization Management in 2026
Prior authorization is a payer’s requirement to approve a service before it happens. Two 2026 changes reshape it for devices:
CMS-0057-F (finalized January 17, 2024) applies to Medicare Advantage, Medicaid, CHIP and other covered payers. From January 1, 2026, they must decide expedited requests within 72 hours and standard requests within 7 calendar days, and give a specific reason for every denial. QHP issuers on the federally facilitated exchanges are excluded from these timeframes.
The WISeR model adds prior authorization to selected services in traditional Medicare in six states: Arizona, New Jersey, Ohio, Oklahoma, Texas and Washington. According to the Congressional Research Service, it runs from January 1, 2026 to December 31, 2031.
For payer research, utilization management experts now matter as much as policy writers.
How Long Does Medical Device Reimbursement Take?
Medical device reimbursement in the US often takes years after FDA authorization.
Stanford Byers Center for Biodesign survey of innovators and investors: respondents reported an average of 2.6 years to establish coding and 4.7 years to national Medicare coverage. Nationwide coding, coverage and payment took up to 8 years.
Later Stanford study in JAMA Health Forum: breakthrough technologies took a median of 5.7 years to reach even nominal Medicare coverage.
Two federal pathways aim to shorten this for breakthrough devices:
TCET (Transitional Coverage for Emerging Technologies): Final notice effective August 12, 2024. Citing resource limits, CMS expects to accept about five devices per year.
RAPID (Regulatory Alignment for Predictable and Immediate Device): Announced by CMS and FDA on April 23, 2026.
For an eligible Class II or Class III breakthrough device, CMS would issue a proposed NCD the same day FDA authorizes the device. A 30-day comment period would follow.
Law firm analyses describe a target of roughly 60 to 90 days to a final NCD.
At the last check, RAPID was still a proposal, not final policy. Its comment period ran through October 13, 2026.
These timelines vary by device class, site of care, and whether existing codes apply. Survey averages are not forecasts for any single product.
How Does Device Reimbursement Work Outside the US?
Outside the US, device reimbursement usually runs through health technology assessment (HTA), then through national or regional funding mechanisms. HTA is a formal review of a technology’s clinical and economic value. Who decides depends on the site of care. Mediclever’s international guide shows this with country codes such as Germany’s OPS, France’s CCAM and England’s OPCS.
| Market | Key body or mechanism | What changed recently |
|---|---|---|
| European Union | EU HTA Regulation (EU) 2021/2282; joint clinical assessments (JCAs) | Applies from January 12, 2025. The 2026 work programme of the EU’s HTA Coordination Group planned about 5 JCAs of selected high-risk devices (class IIb/III and class D IVDs), the first expected from June 2026. It also planned 2 to 5 joint scientific consultations for devices. |
| England | NICE (Early Value Assessment since 2022; HealthTech guidance) | On February 9, 2026, NICE announced the National HealthTech Access Programme. It expands NICE’s Technology Appraisals so that “a small selection of high-impact technologies will be reimbursed and made available across the entire health service.” First final guidance is targeted for Q1 of financial year 2027–28. |
| Germany | NUB requests to InEK for new inpatient methods | Only hospitals can submit, by October 31 each year. Status 1 lets a hospital agree its own fee, valid for one year. AOK reports that 326 of 1,084 methods requested for 2026 received Status 1. |
| France | CNEDiMTS evaluation; LPPR listing; CEPS pricing | — |
For payer research outside the US, recruit former HTA assessors, hospital purchasing heads and sickness fund staff. US-style plan medical directors are the wrong profile.
Who Are Payer Experts?
Payer experts are current or former professionals who make, apply, or price coverage and payment decisions for health plans, government programs, PBMs, or HTA bodies. For medical device research, the most useful profiles are former decision-makers who can explain how a policy was actually written and enforced.
| Payer expert profile | What they know best | Best question to ask | Watch-outs |
|---|---|---|---|
| Former health plan medical director | Medical policy, evidence thresholds, technology assessment committees | “What evidence would move this device from investigational to covered?” | May know one plan’s process only |
| Ex-CMS / Medicare official | NCD process, MAC dynamics, payment rulemaking | “How would CMS likely treat this benefit category?” | 18 U.S.C. 207; no non-public agency information |
| Commercial payer executive | Contracting, network strategy, budget impact | “Would this device change hospital contracting?” | Strategic, less clinical detail |
| HEOR expert | Cost-effectiveness, budget impact models, value dossiers | “Which economic endpoint will payers trust?” | Often industry-side |
| Coverage and coding specialist | CPT/HCPCS fit, claims edits, billing pathways | “Can this be billed under an existing code?” | Not a coverage decision-maker |
| Utilization management expert | Prior authorization criteria, review vendors, denials | “How would this be reviewed under prior authorization?” | Must be recent given 2026 changes |
| PBM expert | Pharmacy-benefit coverage for drug-device combinations and some devices | “Would this sit under the pharmacy or medical benefit?” | Relevant only for pharmacy-benefit routes |
Why Recruit Payer Experts for Market Access Research?
Recruit payer experts because published policies show what a payer decided, not why or what would change the decision. Qualitative interviews with former decision-makers fill the gap between the policy text and how payers actually behave. Typical uses:
- MedTech due diligence: Test whether a target’s reimbursement assumptions hold up, including coverage timing, payer mix and code fit.
- Launch and pricing strategy: Pressure-test price points against budget impact and DRG/APC economics.
- Evidence planning: Learn which endpoints medical directors trust before a pivotal trial locks in.
- Prior authorization exposure: Estimate how utilization management will treat the device under the 2026 rules.
- Message testing: Check value propositions with people who once wrote the policies.
Payer Experts vs Reimbursement Consultants: Which Do You Need?
Payer experts give you the decision-maker’s view through interviews. Reimbursement consultants build and run the strategy. Most consulting firms already own the strategy and need access to payers.
| Factor | Payer expert (via expert network) | Reimbursement consultancy |
|---|---|---|
| Output | Interview insight, quotes, validation | Strategy, code applications, dossiers |
| Engagement | Hourly calls, panels, surveys | Project retainers |
| Speed | Days | Weeks to months |
| Best for | Validating assumptions, due diligence, message testing | Executing coding, coverage, and payment plans |
| Limitation | Opinion, not a decision | Less direct access to former decision-makers |
The 5-Seat Payer Panel: Which Payer Experts a Device Project Needs
The 5-Seat Payer Panel is Nexus Expert Research’s framework for staffing a medical device payer study: fill one seat for each decision layer that can block reimbursement. A study with an empty seat usually misses the barrier that seat would have spotted.
- Medical policy seat: A former commercial health plan medical director or technology assessment committee member. Covers coverage criteria and evidence thresholds.
- Coding and payment seat: A coverage and coding specialist or hospital revenue cycle lead. Covers code fit, DRG/APC economics, and whether NTAP or pass-through is realistic.
- Utilization management seat: A former prior authorization or UM program lead. Covers how review criteria and denials work in 2026.
- Value seat: An HEOR or payer-side health economics expert. Covers budget impact and which economic evidence payers accept.
- Government program seat: An ex-CMS, MAC or Medicare Advantage policy expert, screened for 18 U.S.C. 207. Covers NCD/LCD and Medicare Advantage behavior.
Add a sixth seat only when the case calls for it. That means a PBM expert for pharmacy-benefit routes, or an HTA assessor for EU and UK launches.
How to Recruit Payer Experts for Medical Device Research
To recruit payer experts for a medical device project, define the decision you need explained, map it to panel seats, set hard screening criteria, and source from scratch when the existing network does not fit. Nexus Expert Research reports that about 6 in 10 of its projects require a custom recruit.
- Write the decision question. For example: “Will top US commercial plans cover Device X in outpatient settings within two years?”
- Map the question to seats using the 5-Seat Payer Panel. Set the payer mix: commercial, Medicare Advantage, traditional Medicare, Medicaid.
- Set screening criteria: role title, plan type, covered lives, therapeutic area, recency, and decision authority (voting committee member vs advisor).
- Check conflicts: current employer, ties to device manufacturers, government service dates.
- Source the experts. Start with the existing network. If that falls short, run a live search through professional associations, alumni networks and trade bodies, as Nexus’s How It Works page describes.
- Run a screening call or written screener that tests real decision experience, not job titles.
- Approve each profile individually before scheduling. Brief each expert on topic boundaries and confidentiality.
Nexus states that initial profiles typically arrive in 24 to 48 hours. A full custom recruit for niche profiles takes 3 to 7 business days.
What to Look For in a Payer Expert: A 7-Point Screen
A strong payer expert has held real decision authority, held it recently, and held it in a payer type and therapeutic area that match your device. Use this 7-point screen before approving any profile:
- Decision authority: Voted on, wrote, or signed off coverage, coding or payment policy. Advising alone is not enough.
- Recency: The payer role is recent enough to reflect 2026 prior authorization and Medicare Advantage rules. Set the cutoff in the brief.
- Payer type fit: Commercial, Medicare Advantage, MAC, Medicaid or PBM experience matches your payer mix.
- Scale: Plan size or covered lives is stated and can be verified.
- Therapeutic and site-of-care fit: Has reviewed similar technologies in the same setting.
- Compliance clearance: No current employer conflict, no MNPI exposure, and government post-employment status confirmed.
- Articulation: Can explain the decision logic and evidence standard, not just the outcome.
Reject a profile if the expert cannot name a specific policy or committee they worked on.
Compliance Rules for Engaging Former Payers and Ex-CMS Officials
Engaging payer experts is legal, but every project needs screening for two risks: federal post-employment rules for former government officials, and material non-public information (MNPI). Expert networks and clients share responsibility for both.
Former Government Officials and 18 U.S.C. 207
18 U.S.C. 207 limits what former federal employees, including former CMS officials, may communicate to the government on behalf of others. It does not ban them from private work. According to CDC ethics guidance summarizing the statute:
- Lifetime ban: No representational contact on particular matters they worked on personally and substantially.
- Two-year ban: Covers matters that were under their official responsibility in their last year of service.
- One-year cooling-off (senior employees): No communication intended to influence their former agency on behalf of anyone. USDA guidance lists the 2026 senior-employee pay threshold as $197,220.
- Two-year cooling-off: Applies to “very senior” employees.
A research interview is usually not representational contact. Even so, it must never involve non-public agency information or a request to contact CMS. Do not recruit current CMS or MAC staff without written confirmation from their ethics office.
MNPI and Confidentiality Screening
MNPI is information that is material to an investment decision and not public. Trading on it, or tipping others, can be insider trading.
February 2011: The SEC charged consultants of the expert network Primary Global Research with tipping inside information.
April 2022 Risk Alert: SEC examiners flagged investment advisers that failed to track expert network calls, review call notes, or monitor related trading.
For MedTech due diligence, require:
- Expert attestations that they will not disclose current-employer or confidential payer contract data.
- Exclusion of current employees of the target company and its direct competitors.
- Topic pre-clearance, and a call log kept for compliance review.
This section is general information, not legal advice. Confirm specifics with your compliance counsel.
When Payer Expert Interviews Are the Wrong Tool
Payer expert interviews are the wrong tool when the question needs a count, a claims trend, or a formal decision rather than a judgment. Use something else in these cases:
- You need prevalence or payer mix numbers. Use claims data or a quantitative B2B survey.
- The policy is already published and unambiguous. Read the NCD, LCD or plan policy first.
- You need an official coding decision. Only the AMA CPT Editorial Panel or CMS can give one.
- You plan fewer than one expert per seat. One voice is an anecdote, not a payer view.
- Your question is about prior authorization, and the expert left their payer role before the 2026 rule changes.
Payer experts predict behavior. They cannot commit their former employers to anything.
Frequently Asked Questions About Payer Expert Research
How much does a payer expert call cost?
Payer expert pricing depends on seniority, rarity and geography.
How many payer interviews does a medical device project need?
Plan at least one expert per seat of the 5-Seat Payer Panel, which means at least five conversations. Add more per seat when payer types differ.
How fast can an expert network recruit a former medical director?
Nexus Expert Research states that initial profiles typically arrive in 24 to 48 hours. Niche custom recruits take 3 to 7 business days.
Can current health plan employees be interviewed?
Sometimes, on general topics. They carry a higher risk of disclosing confidential contract or policy information, so many buyers limit payer research to former employees.
What is the difference between a PBM expert and a medical benefit expert?
A PBM expert knows pharmacy-benefit formularies and drug-device combinations. A medical benefit expert knows procedure and device coverage under medical policy. Most devices sit under the medical benefit.
Is FDA clearance enough to get a device covered?
No. CMS has stated that FDA approval or clearance alone does not entitle a technology to Medicare coverage. Commercial plans apply their own medical policies.
Do payer experts help with CPT code applications?
Coding specialists can assess whether a code fits and how an application might be viewed. The AMA CPT Editorial Panel makes the decision. Formal applications are usually run by reimbursement consultancies and medical societies.
Next Step: Scope Your Payer Panel Before You Write the Discussion Guide
Write your decision question, map it to the five seats, and send that brief to Nexus Expert Research. Nexus recruits from scratch for every engagement. That way the payer profiles match your device, payer mix and geography, from former health plan medical directors to ex-Medicare officials.